The adaptive Just-in-Time compiler in VisualAge Micro Edition Version 1.3 boasts of a new degree of runtime performance in embedded Java application program execution. The technology monitors the ...
Replimune received FDA acceptance for its RP1 BLA resubmission in advanced melanoma, with a PDUFA date set for April 2026. REPL stock surged nearly 100% on the news, but FDA acceptance only restarts ...
Replimune (NASDAQ:REPL) climbed more than 100% on Wednesday as Cantor Fitzgerald upgraded the cancer drug developer, citing a potential reversal of an FDA decision that rejected its lead drug ...
NEW YORK, NY / ACCESS Newswire / July 23, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Replimune Group, Inc. (NASDAQ:REPL) for potential violations of ...
Community driven content discussing all aspects of software development from DevOps to design patterns. Packaged as part of the 2018 version 10 release, the Java var reserved word introduced type ...
Java has been one of the more popular programming languages and computing platforms on the market since Sun Microsystems released it all the way back in 1995. The free-to-download platform has been ...
A monthly overview of things you need to know as an architect or aspiring architect. Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with ...
Scripting functionality in Kotlin did not prove as popular as JetBrains expected, the company said. But Gradle Kotlin DSL and the Custom Scripting API will continue to be supported. JetBrains plans to ...
(RTTNews) - Replimune Group (REPL), a clinical-stage biotechnology company, announced on Thursday that it has submitted a biologics license application to the FDA for RP1, its lead product candidate, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback